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Abstract

Key Points
Question How does the trajectory of

IMPORTANCE Several clinical trials are planned for familial forms of frontotemporal lobar
degeneration (f-FTLD). Precise modeling of brain atrophy in f-FTLD could improve the power to
detect a treatment effect.

atrophy differ between the 3 primary
genetic groups (MAPT, GRN, and
C9orf72) associated with familial

OBJECTIVE To characterize regions and rates of atrophy in the 3 primary f-FTLD genetic groups

frontotemporal lobar degeneration?
Findings Among 160 members of

(MAPT, GRN, and C9orf72) across all disease stages from asymptomatic to dementia.

families affected by familial

DESIGN, SETTING, AND PARTICIPANTS This investigation was a case-control study of participants

frontotemporal lobar degeneration in

enrolled in the Advancing Research and Treatment for Frontotemporal Lobar Degeneration or

this case-control study, MAPT and GRN

Longitudinal Evaluation of Familial Frontotemporal Dementia studies. The study took place at 18

pathogenic variants were associated

North American academic medical centers between January 2009 and September 2018.

with increases in the rate of volume loss

Participants with f-FTLD (n = 100) with a known pathogenic variant (MAPT [n = 28], GRN [n = 33], or

as a function of disease stage, whereas

C9orf72 [n = 39]) were grouped according to disease stage (ie, Clinical Dementia Rating [CDR] plus

C9orf72 expansion carriers showed

National Alzheimer’s Coordinating Center [NACC] FTLD module). Included were participants with at

minimal increases in the rate of volume

least 2 structural magnetic resonance images at presymptomatic (CDR + NACC FTLD = 0 [n = 57]),

loss with disease progression.

mild or questionable (CDR + NACC FTLD = 0.5 [n = 15]), or symptomatic (CDR + NACC FTLD = ⱖ1

Meaning This study advances the

[n = 28]) disease stages. The control group included family members of known pathogenic variant
carriers who did not carry the pathogenic variant (n = 60).

knowledge of between-gene differences
in atrophy rates as a function of disease
severity; treatment studies enrolling

MAIN OUTCOMES AND MEASURES This study fitted bayesian linear mixed-effects models in each
voxel of the brain to quantify the rate of atrophy in each of the 3 genes, at each of the 3 disease
stages, compared with controls. The study also analyzed rates of clinical decline in each of these
groups, as measured by the CDR + NACC FTLD box score.

familial frontotemporal dementia cases
should consider the heterogeneity
conferred by both the altered gene and
the disease stage.

RESULTS The sample included 100 participants with f-FTLD with a known pathogenic variant (mean
[SD] age, 50.48 [13.78] years; 53 [53%] female) and 60 family members of known pathogenic variant
carriers who did not carry the pathogenic variant (mean [SD] age, 47.51 [12.43] years; 36 [60%]
female). MAPT and GRN pathogenic variants were associated with increased rates of volume loss

+ Supplemental content
Author affiliations and article information are
listed at the end of this article.

compared with controls at all stages of disease. In MAPT pathogenic variant carriers, statistically
significant regions of accelerated volume loss compared with controls were identified in temporal
regions bilaterally in the presymptomatic stage, with global spread in the symptomatic stage. For
example, mean [SD] rates of atrophy in the left temporal were −231 [47] mm3 per year during the
presymptomatic stage, −381 [208] mm3 per year during the mild stage, and −1485 [1025] mm3 per
year during the symptomatic stage (P < .05). GRN pathogenic variant carriers generally had minimal
increases in atrophy rates between the presymptomatic and mild stages, with rapid increases in
(continued)
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Abstract (continued)

atrophy rates in the symptomatic stages. For example, in the right frontal lobes, annualized volume
loss was −267 [81] mm3 per year in the presymptomatic stage and −182 [90] mm3 per year in the mild
stage, but −1169 [555] mm3 per year in the symptomatic stage. Compared with the other groups,
C9orf72 expansion carriers showed minimal increases in rate of volume loss with disease progression.
For example, the mean (SD) annualized rates of atrophy in the right frontal lobe in C9orf72 expansion
carriers was −272 (118) mm3 per year in presymptomatic stages, −310 (189) mm3 per year in mildly
symptomatic stages, and −251 (145) mm3 per year in symptomatic stages.
CONCLUSIONS AND RELEVANCE These findings are relevant to clinical trial planning and suggest
that the mechanism by which C9orf72 pathogenic variants lead to symptoms may be fundamentally
different from the mechanisms associated with other pathogenic variants.
JAMA Network Open. 2020;3(10):e2022847. doi:10.1001/jamanetworkopen.2020.22847

Introduction
Frontotemporal lobar degeneration (FTLD) is a neurodegenerative disorder associated with a variety
of pathological mechanisms. As many as 30% of FTLD cases are associated with pathogenic gene
variants that are autosomal dominant (familial forms of FTLD [f-FTLD]), and over half of these are
associated with pathogenic variants in 1 of the following 3 genes: microtubule-associated protein tau
(MAPT [OMIM 157140]), progranulin (GRN [OMIM 138945]), and a repeat expansion in the
chromosome 9 open reading frame 72 (C9orf72 [OMIM 614260]) gene. Pathogenic variants in each
of these genes are associated with overlapping but unique clinical and neuroimaging
manifestations.1-8
Accurate characterization of the natural history of each genetic group is important for clinical
care and clinical trials because precise modeling of the disease course can improve the ability to
detect a treatment effect.9,10 Furthermore, there is a need for a working model of disease and
biomarker progression in f-FTLD to inform hypotheses about when biomarker changes develop in
the course of disease and how biomarkers change over time.11 In addition, natural history data can
help clinicians prognosticate and assist family planning.
Many studies have used brain atrophy to describe the evolution of neurodegeneration in
f-FTLD, yielding the following observations: (1) cross-sectional atrophy can be detected in the
presymptomatic stages, and each genetic group has different regional predilection for
atrophy3,6,8,12-14; (2) atrophy rates in the presymptomatic stages may exceed those of age-matched
control cases5,15,16; (3) the rate of volume loss may accelerate near the transition from asymptomatic
to symptomatic5,13; and (4) volume loss in symptomatic cases is usually well in excess of that in
control cases.16-18 However, conclusions from these observations are tempered because many
analyses focused only on 1 genetic group or disease stage, limiting comparisons across genes and
stages. Moreover, many prior estimates of change over time were derived from cross-sectional rather
than longitudinal data.
The emergence of large, comprehensive studies3,19,20 of f-FTLD that include presymptomatic
and symptomatic pathogenic variant carriers allows direct study of the natural history of disease
using longitudinal observations. The present analysis, based on data from 2 of these large natural
history studies,19,21 addresses limitations in previous work by incorporating longitudinal data across
the disease course in participants carrying the 3 most common f-FTLD–associated pathogenic
variants. Based on theoretical models11 and previous observational studies of Alzheimer disease22,23
and FTLD,13,24 our hypothesis was that pathogenic variants in all 3 genes would produce a nonlinear
pattern of neurodegeneration, with acceleration of volume loss as patients develop symptoms.25 We
investigated this question using longitudinal voxelwise analyses of gray matter volume and assessed
whether comparable results were observed for a clinical measure of daily functioning, the Clinical
JAMA Network Open. 2020;3(10):e2022847. doi:10.1001/jamanetworkopen.2020.22847 (Reprinted)
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Dementia Rating (CDR) plus behavioral and language domains from the National Alzheimer’s
Coordinating Center (NACC) FTLD module (CDR + NACC FTLD).

Methods
Participants
In this longitudinal case-control study, we included 160 members of families affected by f-FTLD, most
of whom were enrolled in the Advancing Research and Treatment for Frontotemporal Lobar
Degeneration (ARTFL) or Longitudinal Evaluation of Familial Frontotemporal Dementia (LEFFTDS)
studies, which were conducted through a consortium of 18 academic medical centers across the
United States and Canada between May 2015 and September 2018. For LEFFTDS,19 at least 1 family
member must have a pathogenic variant in the MAPT, GRN, or C9orf72 genes. For ARTFL,21 families
with any f-FTLD pathogenic variant or without a known pathogenic variant can enroll, but only
carriers of MAPT, GRN, or C9orf72 pathogenic variants were included in this analysis. The ARTFL and
LEFFTDS protocols include annual follow-up with clinical reassessment. Additional f-FTLD cases
included those enrolled in another study26 of FTLD at the University of California, San Francisco, and
who had undergone a similar brain imaging protocol (grants AG032306 and AG019724 from the
National Institutes of Health) from January 2009 to October 2016. Exclusion and inclusion criteria
are provided in the eMethods in the Supplement. Local ethics committees at each of the sites
approved the study, and participants provided written informed consent. This study followed the
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.
The sample included 100 participants with f-FTLD with a known pathogenic variant (MAPT+ [28
individuals with MAPT pathogenic variants], GRN+ [33 individuals with GRN pathogenic variants],
and C9orf72+ [39 individuals with C9orf72 repeat expansions]) and 60 family members of known
pathogenic variant carriers who did not carry the pathogenic variant (demographic characteristics
are listed in the Table and eTable 1 in the Supplement). Participants with f-FTLD were grouped into
the following 3 disease stages using CDR + NACC FTLD27: presymptomatic (CDR + NACC FTLD = 0
[n = 57]), mild or questionable (CDR + NACC FTLD = 0.5 [n = 15]), or symptomatic (CDR + NACC
FTLD = ⱖ1 [n = 28]). Included were participants who had at least 2 structural magnetic resonance
images within 1 of these stages (Table and eTable 1 in the Supplement); all available scans within that
disease stage for each participant were used for the study. Each participant was only included in a
single disease stage.

Clinical Assessment
The multidisciplinary assessment included neurological history and examination and collateral
interview. Neuropsychological tests included the Uniform Data Set (version 3.0) neuropsychological
battery.28 Functional status was quantified using CDR + NACC FTLD27,29,30 (details are provided in
the Supplement). Brain imaging was not used for diagnosis or severity rating. Clinical diagnoses are
listed in eTable 2 in the Supplement. All participants had genetic testing at the University of
California, Los Angeles, using published methods31 (specific pathogenic variants are provided in the
eAppendix in the Supplement).

Neuroimaging
Image Acquisition
Participants underwent 3 tesla (3-T) imaging on MRI scanners (scanner types are listed in eTable 3 in
the Supplement). A standard imaging protocol was used across all centers and was managed and
reviewed for quality by a core group (including K.K.) at the Mayo Clinic, Rochester, Minnesota. Details
of image acquisition, processing, and harmonization are provided in the eMethods in the Supplement
and have been published elsewhere.8 All participants except 3 were scanned on the same scanner
at all visits (for 2 participants, the scanner was upgraded; the third changed sites).
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Bayesian Voxelwise Mixed-Effects Modeling
Group-level and participant-level rates of atrophy at each brain voxel were longitudinally modeled as
a function of age using a bayesian hierarchical mixed-effects framework32 introduced by Friston and
colleagues33 and reproduced in our in-house software suite at the Memory and Aging Center,
University of California, San Francisco. The model consists of the following 2 hierarchical levels: (1) a
single-participant level for individual structural trajectories and (2) a group level for an ensemble of
trajectories (eMethods in the Supplement). Researchers interested in the code for the bayesian
mixed-effects models can find information in the publication by Zeigler and colleagues32 or may
contact the corresponding author of this study.

Statistical Analysis
Details of the analytic approach are provided in the eMethods in the Supplement. To address the
main hypothesis that f-FTLD pathogenic variants are associated with high rates of volume loss that
increase with disease stage, we examined voxelwise maps of rates of annualized brain volume loss at
each disease stage in each genetic group and compared these with rates in the control group. We fit
a 3-way interaction model at each voxel as the rate of atrophy by disease stage by gene. Statistically
significant voxels indicated that the association of increasing disease stage with volume loss is
moderated by gene. Voxelwise maps showing where rates of volume loss were statistically
significantly increased in the pathogenic variant carrier groups compared with the control group
were produced using the FMRIB Software Library.34,35 To understand the cumulative associations of
volume loss, we analyzed cross-sectional volume using the last observation for all participants in
their disease stage.34 P < .05 was considered statistically significant, and all tests were 2 tailed.
To summarize rates of volume loss in various brain regions, we analyzed data for several large
regions of interest (ROIs),36 including bilateral frontal, temporal, parietal, and occipital lobes and the

Table. Sample Characteristics
Characteristic

Control cases

All pathogenic
variant carriers

MAPT

GRN

C9orf72

Group comparisona

P value

Post hocb

No. of individuals
(No. of visits)

60 (138)

100 (250)

28 (68)

33 (81)

39 (101)

NA

NA

NA

Age, mean (SD), y

47.51 (12.43)

50.48 (13.78)

43.97 (11.49)

56.89 (13.52)

50.50 (12.94)

F2,97 = 7.21

.001

MAPT < GRN
and C9orf72

Educational level,
mean (SD), y

15.61 (2.61)

15.35 (2.48)

15.56 (2.17)

15.40 (2.55)

15.17 (2.63)

F2,97 = 0.69

.50

NA

Female

36/60 (60)

53/100 (53)

23/39 (59)

19/33 (58)

11/28 (39)

NA

NA

NA

Male

24/60 (40)

47/100 (47)

16/39 (41)

14/33 (42)

17/28 (61)

χ2 = 4.24

.12

NA

Sex, No./total No. (%)

Race/ethnicity, No./total
No. (%)
White

57/60 (95)

93/100 (93)

38/39 (97)

28/33 (85)

27/28 (96)

NA

NA

NA

Otherc

3/60 (5)

7/100 (7)

1/39 (3)

5/33 (15)

1/28 (4)

NA

NA

NA

NA

Functional severity, No. of
individuals (No. of visits)
CDR + NACC FTLD = 0

60 (138)

57 (142)

19 (47)

18 (42)

20 (53)

NA

NA

CDR + NACC FTLD = 0.5

NA

15 (35)

4 (9)

6 (14)

5 (12)

NA

NA

NA

CDR + NACC FTLD = ≥1d

NA

28 (73)

5 (12)

9 (25)

14 (36)

NA

NA

NA

CDR + NACC FTLD = 1

NA

12 (31)

2 (5)

7 (18)

3 (8)

NA

NA

NA

CDR + NACC FTLD = 2

NA

14 (37)

2 (4)

2 (7)

10 (26)

NA

NA

NA

CDR + NACC FTLD = 3

NA

2 (5)

1 (3)

0

1 (2)

NA

NA

NA

Abbreviations: CDR + NACC FTLD, Clinical Dementia Rating plus National Alzheimer’s
Coordinating Center Frontotemporal Lobar Degeneration; NA, not applicable.

c

Other includes Native American, Asian, Asian Indian, Mixed, and not reported. These
groups were combined to protect confidentiality.

a

MAPT, GRN, and C9orf72 groups were compared on age and educational level using
regression and on sex using χ2 test.

d

The 3 rows below are the detailed breakdown for CDR + NACC FTLD = ⱖ1.

b

Post hoc comparisons reported if P < .05 for group difference.
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thalamus and cerebellum. Thalamic and cerebellar ROIs were chosen because of their involvement in
f-FTLD.3,6 For each ROI, we extracted the specific slope of each participant.
To examine patterns of change in clinical measures, we created linear mixed-effects regression
models using participant-specific rates of change in CDR + NACC FTLD box score as the dependent
variable. Higher box scores indicate more severe functional impairment. Analysis of clinical data was
performed using Stata, version 14.2 (StataCorp LLC).

Results
The sample included 100 participants with f-FTLD; the mean (SD) age was 50.48 (13.78) years, 53
(53%) were female, and 47 (47%) were male. Noncarriers made up a control group with otherwise
similar genetic and environmental backgrounds compared with the carriers. The control group
included 60 family members; the mean (SD) age was 47.51 (12.43) years, 36 (60%) were female, and
24 (40%) were male.

Longitudinal Atrophy Rates
Maps of annualized rates of atrophy (Figures 1, 2, and 3 and eFigure 1 in the Supplement) revealed
statistically significant increases in the rate of volume loss for pathogenic variant carriers compared
with control cases for all genes at all stages. The mean (SD) regional rates of atrophy for control

Figure 1. Maps of Voxelwise Atrophy Rate in MAPT Pathogenic Variant Carriers at 3 Levels of Disease Severity
MAPT
CDR + NACC FTLD = 0

CDR + NACC FTLD = 0.5

CDR + NACC FTLD = ≥1

A Voxelwise atrophy rates in cubic millimeters per year for pathogenic variant carriers

0

B

0.2

Significance maps comparing atrophy rates of pathogenic variant carriers with controls

P <.05
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A, More positive values represent faster rates of
atrophy. Based on our hypothesis, only those voxels
that show rates of atrophy are presented; extending
the color scale to voxels that were estimated to show
volume growth would decrease interpretability by
compressing the color scale in voxels of interest (those
showing volume loss). B, Green voxels are statistically
significant at P < .05 after familywise error correction
for multiple comparison at each voxel. Statistically
significant increased rates of volume loss compared
with controls were observed at all stages. Statistically
significant regions of accelerated volume loss were
identified in temporal regions bilaterally in the
presymptomatic stage and mild or questionable stage,
with global spread in the symptomatic stage; the
largest effect sizes were observed in the frontal and
temporal lobes. CDR + NACC FTLD indicates Clinical
Dementia Rating plus National Alzheimer’s
Coordinating Center Frontotemporal Lobar
Degeneration.
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participants (eTable 4 in the Supplement) were as follows for 6 lobes of interest: −170 (12) mm3 per
year for left frontal, −160 (15) mm3 per year for right frontal, −77 (13) mm3 per year for left frontal, −73
(17) mm3 per year for right temporal, −105 (14) mm3 per year for left parietal, and −102 (16) mm3 per
year for right parietal.
In MAPT+ carriers, statistically significant regions of accelerated volume loss compared with
controls (P < .05 for all) were identified in temporal regions bilaterally in the presymptomatic stage.
In the ROI analysis, mean (SD) values were −231 (47) mm3 per year for left temporal and −150 (36)
mm3 per year for right temporal lobe. For the mild or questionable stage, the mean (SD) values were
−381 (208) mm3 per year for left temporal and −315 (201) mm3 per year for right temporal lobe.There
was global spread in the symptomatic stage. The largest effect sizes were observed in the frontal
and temporal lobes (Figure 1). The mean (SD) values were −2269 (1574) mm3 per year for the left
frontal lobe, −2053 (2006) mm3 per year for right frontal lobe, −1485 (1025) mm3 per year for left
temporal, and −1164 (882) mm3 per year for right temporal lobe.
In GRN+ carriers, the rate of volume loss was fairly uniform across the brain in the
presymptomatic and mild stages, with little evidence of acceleration between stages. For example,
in the ROI analysis, annualized right frontal volume loss was −267 (81) mm3 per year in the
presymptomatic stage and −182 (90) mm3 per year in the mild stage. The exception was a possible
area of accelerated atrophy in the putamen (Figure 2). With development of dementia, GRN+ carriers
showed accelerated loss of volume in portions of the frontal (mean [SD], −1530 [388] mm3 per year

Figure 2. Maps of Voxelwise Atrophy Rate in GRN Pathogenic Variant Carriers at 3 Levels of Disease Severity
GRN
CDR + NACC FTLD = 0

CDR + NACC FTLD = 0.5

CDR + NACC FTLD = ≥1

A Voxelwise atrophy rates in cubic millimeters per year for pathogenic variant carriers

0

B

0.2

Significance maps comparing atrophy rates of pathogenic variant carriers with controls

P <.05
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A, More positive values represent faster rates of
atrophy. Based on our hypothesis, only those voxels
that show rates of atrophy are presented; extending
the color scale to voxels that were estimated to show
volume growth would decrease interpretability by
compressing the color scale in voxels of interest (those
showing volume loss). B, Green voxels are statistically
significant at P < .05 after familywise error correction
for multiple comparison at each voxel. Statistically
significant increased rates of volume loss compared
with controls were observed at all stages. In GRN+, the
rate of volume loss was fairly uniform across the brain,
with little evidence of acceleration between the
presymptomatic stage and mild or questionable stage
except for a possible area of accelerated atrophy in
the putamen. With development of dementia, GRN+
showed accelerated loss of volume in portions of the
frontal, temporal, and parietal lobes bilaterally. CDR +
NACC FTLD indicates Clinical Dementia Rating plus
National Alzheimer’s Coordinating Center
Frontotemporal Lobar Degeneration.
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for left frontal and −1169 [555] mm3 per year for right frontal ROIs), temporal (mean [SD], −867 [308]
mm3 per year for left temporal and −433 [119] mm3 per year for right temporal ROIs), and parietal
(mean [SD], −896 [217] mm3 per year for left parietal and −484 [108] mm3 per year for right parietal
ROIs) lobes bilaterally.
In contrast to pathogenic variants in the other 2 genes, C9orf72+ carriers showed minimal
increase in atrophy rates across disease stages (Figure 3). For example, in the ROI analysis, the mean
(SD) annualized right frontal lobe volume loss was −272 (118) mm3 per year in the presymptomatic
stage, −310 (189) mm3 per year in the mild or questionable stage, and −251 (145) mm3 per year in the
symptomatic stage. Regions with the largest effect sizes were distributed among frontal (mean [SD],
−285 [199] mm3 per year for left frontal and −251 [145] mm3 per year for right frontal ROIs), temporal
(mean [SD], −77 [44] mm3 per year for left temporal and −64 [46] mm3 per year for right temporal
ROIs), and parietal (mean [SD], −122 [157] mm3 per year for left parietal and −124 [160] mm3 per year
for right parietal ROIs) regions in C9orf72+.
Because the maps of volume loss indicated differences in rates of stage-dependent volume loss
across groups, we fit an omnibus, disease stage by gene interaction model for rates of volume loss
at each voxel. Almost every voxel in the brain (91% [247 910 of 273 039 voxels]) showed a
statistically significant interaction (eFigure 2 in the Supplement), indicating that the association of
disease severity with atrophy rates differs across genetic groups.

Figure 3. Maps of Voxelwise Atrophy Rate in C9orf72 Repeat Expansion Carriers at 3 Levels of Disease Severity
C9orf72
CDR + NACC FTLD = 0

CDR + NACC FTLD = 0.5

CDR + NACC FTLD = ≥1

A Voxelwise atrophy rates in cubic millimeters per year for pathogenic variant carriers

0

B

0.2

Significance maps comparing atrophy rates of pathogenic variant carriers with controls

P <.05
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A, More positive values represent faster rates of
atrophy. Based on our hypothesis, only those voxels
that show rates of atrophy are presented; extending
the color scale to voxels that were estimated to show
volume growth would decrease interpretability by
compressing the color scale in voxels of interest (those
showing volume loss). B, Green voxels are statistically
significant at P < .05 after familywise error correction
for multiple comparison at each voxel. Statistically
significant increased rates of volume loss compared
with controls were observed at all stages. In contrast to
carriers of pathogenic variants in the other 2 genes,
C9orf72 repeat expansion carriers showed little
acceleration across disease stages, even with
transition to dementia. Regions with the largest effect
sizes were distributed among frontal, temporal, and
parietal regions in C9orf72+. CDR + NACC FTLD
indicates Clinical Dementia Rating plus National
Alzheimer’s Coordinating Center Frontotemporal
Lobar Degeneration.
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The ROI analysis highlighted the increases in the rate of volume loss for MAPT+ between the
presymptomatic and mild or questionable stages in the right (mean [SD], −277 [119] mm3 per year for
presymptomatic and −576 [276] for mild or questionable) and left (mean [SD], −259 [99] mm3 per
year for presymptomatic and −544 [301] mm3 per year for mild or questionable) frontal, temporal
(eg, mean [SD], −231 [47] mm3 per year for presymptomatic and −381 [208] for mild or questionable
for left temporal), and parietal (eg, mean [SD], −139 [27] mm3 per year for presymptomatic and −303
[151] for mild or questionable for left parietal) regions (Figure 4 and eFigure 3 and eTable 4 in the
Supplement). Smaller increases in the rate of volume loss with increasing disease severity were
observed in the occipital lobes (mean [SD], −38 [10] for presymptomatic and −110 [68] for mild or
questionable) and thalamus (mean [SD], −13 [13] for presymptomatic and −78 [50] for mild or
questionable). The ROI analysis also underscored how the genetic groups differed in the degree of
increased atrophy when transitioning from the mild to symptomatic stage. Even in regions where the
rate of volume loss increased between the mild and symptomatic stages in C9orf72+ carriers, the
magnitude of acceleration of atrophy between these 2 stages was much higher in MAPT+ and GRN+
carriers. For example, in the right frontal lobe, the increase in atrophy rate between the 2 stages was
about 6 to 9 times higher in GRN+ (mean [SD], −182 [90] for mild or questionable and −1169 [555]
for symptomatic) and MAPT+ (mean [SD], −576 [276] for mild or questionable and −2053 [2006] for
symptomatic) carriers, respectively, compared with C9orf72+ (mean [SD], −310 [189] for mild or
questionable and −251 [145] for symptomatic) carriers (eTable 4 in the Supplement). Overall, these
data supported the voxelwise pattern of results.
One potential reason why the rate of volume loss may appear erroneously low in the C9orf72+
group is that the spatial location of atrophy may vary across C9orf72+ carriers, such that mean rates of
change in any single region might be low at the group level. We examined this question by creating

Figure 4. Mean Rates of Volume Loss for Frontal and Temporal Regions of Interest
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Examination of mean rates of volume loss in several regions of interest highlights how
the consequences of disease stage vary by genetic group, with C9orf72 repeat expansion
carriers showing the least increase in the rate of atrophy as disease severity increases.
GRN pathogenic variant carriers showed almost no differences in the rate of volume loss
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between CDR + NACC FTLD 0 and 0.5 stages, whereas a large increase in the rate of
volume loss was observed between the 0.5 and 1 or greater stages. CDR + NACC FTLD
indicates Clinical Dementia Rating plus National Alzheimer’s Coordinating Center
Frontotemporal Lobar Degeneration. Error bars indicate SDs.
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voxelwise maps of variance in rates of change (eFigure 4 in the Supplement) and by plotting mean
lobar rates of change for each pathogenic variant carrier (eFigure 5 in the Supplement) for each
genetic group at each stage. We also created maps of annualized volume loss for each individual in
the CDR + NACC FTLD = 1 or greater stage (eFigure 6 in the Supplement). These maps and plots
revealed that variability was highest in MAPT+ and lowest in C9orf72+ carriers, suggesting that
excessive variability across C9orf72+ carriers, either in the spatial location of atrophy or the rate of
atrophy, does not account for the group-level findings.

Clinical Decline
Rates of functional decline, as measured by the CDR + NACC FTLD box score, showed a disease stage
by gene interaction, similar to the rates of atrophy (bottom of eTable 4 in the Supplement). In
contrast to the imaging results, the C9orf72+ and GRN+ groups showed similar differences in the rate
of change from 0 (mean [SD], 0.1 [0] box score units per year for C9orf72+ and 0.1 [0] box score units
per year for GRN+) to 0.5 (mean [SD], 0.4 [0.1] box score units per year for C9orf72+ and 0.3 [0.2]
box score units per year for GRN+) and from 0.5 to 1 (mean [SD], 1.5 [0.3] box score units per year for
C9orf72+ and 1.4 [0.5] box score units per year for GRN+). The estimated difference in rate of clinical
decline from 0.5 (mean [SD], 0.3 [0.1] for MAPT+) to 1 (mean [SD], 2.2 [1.0] for MAPT+) was almost
twice as large in the MAPT+ group as it was for GRN+ or C9orf72+ groups, consistent with
neuroimaging.

Cross-sectional Atrophy
The small increases in the rate of volume loss in the C9orf72+ group prompted the question of
whether expansions in this gene are associated with accumulation of brain atrophy to a similar
degree as pathogenic variants in the other genes. Voxelwise maps depicting cross-sectional atrophy
at each stage in each gene are shown in eFigure 7A, C, and E in the Supplement, with maps of
statistical significance shown in eFigure 7B, D, and F in the Supplement. At CDR + NACC FTLD = 1 or
greater, all groups showed more atrophy in all ROIs compared with the control group (eFigure 8 and
eTable 5 in the Supplement). The MAPT+ group showed the greatest degree of frontal (mean [SD]
volume, left frontal: 12 683 [2345] mm3; right frontal: 13 235 [2015] mm3) and temporal (mean [SD]
volume, left temporal: 8652 [1090] mm3; right temporal: 8628 [1237] mm3) atrophy at this stage,
followed by GRN+ (eg, mean [SD] volume, right frontal: 13 679 [2448] mm3; right temporal: 9271
[1530] mm3) and C9orf72+ groups (eg, mean [SD] volume, right frontal: 14 012 [1485] mm3; right
temporal: 9336 [734] mm3), with similar degrees of atrophy in GRN+ and C9orf72+ groups.

Discussion
The objective of this study was to characterize the evolution of neurodegeneration in FTLD
associated with pathogenic variants in 3 different genes. Consistent with our hypothesis, we found
evidence for acceleration of neurodegeneration, as measured by loss of brain volume, in MAPT+ and
GRN+. Compared with these 2 genetic groups, C9orf72+ was associated with attenuated increases in
the rate of volume loss, even with transition to dementia. The differences in mean rates of change
across groups were not accounted for by differences in interparticipant variability. Despite
differences in patterns of acceleration, cross-sectional maps of atrophy indicated that pathogenic
variants in all 3 genes were associated with substantial accumulation of atrophy by the time patients
developed dementia. Progression in a clinical measure of disease severity diverged from this pattern,
with the rate of functional decline in C9orf72+ being similar to that in GRN+. Together, these findings
suggest that, although the destiny for the brain in C9orf72+ is similar to that of other pathogenic
variants, the path to this point is different, being slower and more constant over time. This finding
has implications for models that would target prediction of symptom onset or tracking of disease
progression. In addition, it raises important questions about the unique pathophysiology associated
with C9orf72 repeat expansions and how this finding relates to symptoms.
JAMA Network Open. 2020;3(10):e2022847. doi:10.1001/jamanetworkopen.2020.22847 (Reprinted)
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These results have several implications for work predicated on accurate prognostication.
Treatment studies enrolling groups with f-FTLD must consider the heterogeneity conferred by both
the disease stage and the altered gene. In addition, a critical goal for trials in f-FTLD is to identify
predictors for when symptoms will develop so that participants who are close to symptom onset and
demonstrate delay in this transition can be enrolled.37-39 Recent publications from studies of f-FTLD
and other familial neurodegenerative diseases indicate that cross-sectional40 and longitudinal5
measurements of imaging and fluid biomarkers can predict development of symptoms. Our results
suggest that models assuming rapid change in biomarkers preceding or accompanying development
of symptoms may apply well to MAPT+ and GRN+ carriers, but not as well to C9orf72+ carriers.
However, whereas the nonlinear nature of change in MAPT+ and GRN+ may make it difficult to predict
onset of symptoms using measures collected in the stable or asymptomatic phase, such
measurements may be more useful in C9orf72+, where decline is more linear.
Different dynamics of change across these 3 genetic groups may be associated with the unique
pathophysiology of pathogenic variants in each gene. We observed regions of accelerated volume
loss in the medial temporal regions relative to the rest of the brain in MAPT+ early in the course of
illness. This finding indicates fairly consistent associations in this region across participants,
consistent with prior literature,3,4,13 indicating that the medial temporal lobes are particularly
vulnerable to MAPT pathogenic variants. The MAPT pathogenic variants lead to accumulation of
modified tau molecules that damage neurons, although the mechanisms are not completely
understood,41 and our model suggests that the associations of interventions in the early stages of
disease might be measurable in reduced rates of volume loss in medial temporal regions or reduced
spread of atrophy to other regions. Compared with the other genetic groups, MAPT+ tends to exhibit
atrophy more focally and symmetrically, which could improve the power to detect atrophy at the
group level.
In contrast to MAPT+, little acceleration of volume loss occurred in any region until symptom
onset in GRN+. This observation is consistent with studies showing minimal cross-sectional13,42 or
longitudinal2,15,42 atrophy in presymptomatic GRN+. Moreover, other studies have shown that rapid
neuroimaging changes13 and 3-fold to 4-fold increases in cerebrospinal fluid neurofilament light
chain levels43 occur around the time of symptom onset in GRN+. The primary consequence of the
GRN pathogenic variant is reduced production of the progranulin protein. This reduction is
detectable early in life, and levels of progranulin are similar in the presymptomatic and symptomatic
stages, indicating that progranulin reduction may not be directly responsible for symptoms.44-46
These observations could be consistent with the theory that a secondary biological process (“hit”)
occurring in the context of low progranulin sets off a rapid cascade of neurodegeneration13 or that
there is a tipping point in the accumulation of cellular or tissue damage. If this 2-hit model does
indeed apply to GRN+, progranulin-raising medications administered in the presymptomatic stage
may delay onset of symptoms but might have only a minimal impact on measurable imaging changes
in this phase.
The observation that C9orf72+ showed only a small degree of acceleration yet the degree of
volume loss accumulated was close to the amount seen with GRN+ in the symptomatic phase might
suggest that atrophy starts at a younger age, which is supported by previous studies.6,12
Furthermore, studies15,47-49 of small cohorts of C9orf72+ have highlighted slow progression with
insidious transition from presymptomatic to symptomatic phases. Our findings indicate that this
insidious transition may be a common feature of disease associated with C9orf72 repeat expansions,
although rapid deterioration may still occur in some cases or later in the illness.50 Divergence in rates
of volume loss and clinical decline in C9orf72+ is consistent with prior findings suggesting that
neuronal dysfunction (particularly salience network and medial pulvinar dysfunction quantified with
task-free functional magnetic resonance imaging) rather than global neuronal loss may best predict
clinical severity in C9orf72+.49
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Limitations
These results should be interpreted in the context of several limitations. First, because of the rarity
of this disease, the sample sizes are small. Although the longitudinal nature of this study improves
our ability to directly quantify changes, replication will be important given the small sample sizes in
some of the groups. A second consequence of the small sample size is that, although we separated
participants into 3 genetic groups, we were unable to look at the association of specific pathogenic
variants, which produce overlapping but distinct atrophy patterns51,52 and different disease
durations.20 We addressed this limitation in part by producing variability maps to understand the
consequences of within-group heterogeneity. Third, the small sample size required careful
consideration of covariates, and we were unable to fully explore all potential factors, such as sex. This
limitation is a topic that will be the focus of future investigation.

Conclusions
To our knowledge, this investigation is the first study to analyze the natural history of longitudinal
volumetric changes in pathogenic variant carriers in 3 genes, across the entire disease spectrum. This
study advances the knowledge of between-gene differences in atrophy rates as a function of disease
severity, and the results have implications for clinical trial design. These findings suggest that the
mechanism by which C9orf72 pathogenic variants engender symptoms may be fundamentally
different from the mechanisms associated with MAPT and GRN pathogenic variants.
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